Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Brexucabtagene autoleucel versus standard of care for untreated high-risk mantle cell lymphoma
NL-OMON60303Phase 2Recruiting
- Sponsor
- LMU Klinikum
- Start
- Feb 2026
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Gene Therapies
- Countries
- 1
01
Overview
Phase 2 trial of brexucabtagene autoleucel, sponsored by LMU Klinikum. Started Feb 2026; status: recruiting.
02
Drugs
brexucabtagene autoleucel
Beyond the preview
Go deeper on NL-OMON60303.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60303.